Tarek Mansour - InMed Pharmaceuticals Director
Director
Dr. Tarek Mansour Ph.D. is Director of the Company. Dr. Mansour was previously with Xenon Pharmaceuticals as its executive vicepresident. He also held similar positions at Pfizer and Wyeth Pharmaceuticals prior to founding Sabila Biosciences LLC where he is currently the chief executive officer. Dr. Mansour expertise spans multiple therapeutic areas including antiinfectives oncology inflammatory metabolic cardiovascular and pain. Under his leadership several compounds have progressed to various stages of clinical evaluation including Food and Drug Administration approvals and latestage development. Amongst these candidates are Epivir Zeffix Troxatyl Bosulif Neratinib and PFE384 since 2015.
| Tenure | 9 years |
| Phone | 604 669 7207 |
| Web | http://www.inmedpharma.com |
InMed Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (50.41) % which means that it has lost $50.41 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (91.74) %, meaning that it generated substantial loss on money invested by shareholders. InMed Pharmaceuticals' management efficiency ratios could be used to measure how well InMed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Andrew Balson | Dominos Pizza | 54 | |
| Diana Cantor | Dominos Pizza | 63 | |
| James Goldman | Dominos Pizza | 62 | |
| Michael Cavanagh | Yum Brands | 53 | |
| Tanya Domier | Yum Brands | 55 | |
| Ramon Phillips | Rave Restaurant Group | 84 | |
| Elane Stock | Yum Brands | 55 | |
| Robert Walter | Yum Brands | 71 | |
| Mirian GraddickWeir | Yum Brands | 65 | |
| Jonathan Linen | Yum Brands | 70 | |
| Scott Ford | Westrock Coffee | 61 | |
| Christopher Connor | Yum Brands | 65 | |
| Andy Ballard | Dominos Pizza | 41 | |
| Keith Meister | Yum Brands | 41 | |
| Brian Bares | Rave Restaurant Group | 43 | |
| William Hammett | Rave Restaurant Group | 71 | |
| Clinton Coleman | Rave Restaurant Group | 40 | |
| Margaret Randazzo | Westrock Coffee | 46 | |
| Mark Kalow | Westrock Coffee | 59 | |
| Lisa Schlepp | Rave Restaurant Group | N/A | |
| Robert Page | Rave Restaurant Group | 58 | |
Management Performance
| Return On Equity | -91.74 | |||
| Return On Asset | -50.41 |
InMed Pharmaceuticals Leadership Team
Elected by the shareholders, the InMed Pharmaceuticals' board of directors comprises two types of representatives: InMed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InMed. The board's role is to monitor InMed Pharmaceuticals' management team and ensure that shareholders' interests are well served. InMed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InMed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Charpentier, CFO, Corporate Secretary | ||
| Craig Schneider, CEO and President Director and Member of Audit Committee | ||
| Andrew Hullh, Director | ||
| Eric Adams, President CEO, Director | ||
| Andrew Hull, Director | ||
| Paul Brennan, President CEO, Director | ||
| Alexandra Mancini, Senior Vice President - Clinical and Regulatory Affairs | ||
| Abo Mohammed, Chief Medical Officer | ||
| William Garner, Director | ||
| Chris Bogart, Interim CEO | ||
| Tarek Mansour, Director | ||
| Martin Bott, Director | ||
| Catherine Sazdanoff, Director | ||
| Terese Gieselman, Chief Financial officer | ||
| Adam Cutler, Director | ||
| Stephen Tong, Director | ||
| Josh Blacher, Chief Business Officer |
InMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is InMed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -91.74 | |||
| Return On Asset | -50.41 | |||
| Current Valuation | 35.74 M | |||
| Shares Outstanding | 158.2 K | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Earning | (11.11) X | |||
| Price To Book | 60.57 X | |||
| EBITDA | (7.19 M) | |||
| Net Income | (7.17 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the InMed Pharmaceuticals information on this page should be used as a complementary analysis to other InMed Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in InMed OTC Stock
If you are still planning to invest in InMed Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InMed Pharmaceuticals' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |